Now showing items 1-10 of 11
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
BACKGROUND: Alemtuzumab is a CD52-specific monoclonal antibody that markedly depletes T and B lymphocytes and inhibits relapsing multiple sclerosis (MS). However, polymorphonuclear neutrophils also express CD52 and can be ...
Both cladribine and alemtuzumab may effect MS via B-cell depletion.
OBJECTIVE: To understand the efficacy of cladribine (CLAD) treatment in MS through analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine and alemtuzumab induction therapies. ...
Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.
BACKGROUND: In multiple sclerosis (MS) upper limb neurological impairments, are an important driver of disability and handicap. The gold standard for assessing upper limb function is the 9-hole peg test (9HPT). One ...